Ou SH & Soo RA. (2015). Dacomitinib in lung cancer: A “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? Dove Medical Press.
Chicago Style (17th ed.) CitationOu SH and Soo RA. Dacomitinib in Lung Cancer: A “lost Generation” EGFR Tyrosine-kinase Inhibitor from a Bygone Era? Dove Medical Press, 2015.
MLA (9th ed.) CitationOu SH and Soo RA. Dacomitinib in Lung Cancer: A “lost Generation” EGFR Tyrosine-kinase Inhibitor from a Bygone Era? Dove Medical Press, 2015.
Warning: These citations may not always be 100% accurate.